Aggressive multiple sclerosis (2): Treatment

被引:23
作者
Arrambide, Georgina [1 ]
Iacobaeus, Ellen [2 ]
Amato, Maria Pia [3 ,4 ]
Derfuss, Tobias [5 ,6 ]
Vukusic, Sandra [7 ,8 ,9 ,10 ]
Hemmer, Bernhard [11 ,12 ,13 ]
Brundin, Lou [2 ]
Tintore, Mar [1 ]
机构
[1] Univ Autonoma Barcelona, Serv Neurol Neuroimmunol, Ctr Esclerosi Multiple Catalunya Cemcat, Vall dHebron Inst Recerca,Hosp Univ Vall dHebron, Edifici Cemcat,Pg Vall dHebron 119-129, Barcelona 08035, Spain
[2] Karolinska Inst, Div Neurol, Dept Clin Neurosci, Stockholm, Sweden
[3] Univ Florence, Dept NEUROFARBA, Florence, Italy
[4] IRCCS Fdn Don Carlo Gnocchi, Florence, Italy
[5] Univ Basel, Univ Basel Hosp, Dept Neurol, Basel, Switzerland
[6] Univ Basel, Univ Basel Hosp, Dept Biomed, Basel, Switzerland
[7] Hosp Civils Lyon, Hop Neurol Pierre Wertheimer, Serv Neurol Sclerose Plaques Pathol Myeline & Neu, Lyon, France
[8] Hosp Civils Lyon, Hop Neurol Pierre Wertheimer, Ctr Reference Malad Inflammatoires Rares Cerveau, Lyon, France
[9] INSERM 1028, Ctr Neurosci Lyon, Observ Francais Sclerose Plaques, Lyon, France
[10] CNRS, UMR5292, Lyon, France
[11] Univ Claude Bernard Lyon 1, Fac Med Lyon Est, Lyon, France
[12] Tech Univ Munich, Sch Med, Klinikum Rechts Isar, Dept Neurol, Munich, Germany
[13] Munich Cluster Syst Neurol SyNergy, Munich, Germany
关键词
Aggressive; highly active; multiple sclerosis; disability; relapsing-remitting; treatment response; STEM-CELL TRANSPLANTATION; CENTRAL-NERVOUS-SYSTEM; FINGOLIMOD SUBGROUP ANALYSES; DISEASE-MODIFYING THERAPIES; PLASMA-EXCHANGE THERAPY; BG-12 DIMETHYL FUMARATE; DOUBLE-BLIND; PRACTICE GUIDELINE; CNS DEMYELINATION; CLINICAL-EFFICACY;
D O I
10.1177/1352458520924595
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The natural history of multiple sclerosis (MS) is highly heterogeneous. A subgroup of patients has what might be termed aggressive MS. These patients may have frequent, severe relapses with incomplete recovery and are at risk of developing greater and permanent disability at the earlier stages of the disease. Their therapeutic window of opportunity may be narrow, and while it is generally considered that they will benefit from starting early with a highly efficacious treatment, a unified definition of aggressive MS does not exist and data on its treatment are largely lacking. Based on discussions at an international focused workshop sponsored by the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), we review our current knowledge about treatment of individuals with aggressive MS. We analyse the available evidence, identify gaps in knowledge and suggest future research needed to fill those gaps. A companion paper details the difficulties in developing a consensus about what defines aggressive MS.
引用
收藏
页码:1045 / 1063
页数:19
相关论文
共 86 条
[1]   Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial [J].
Atkins, Harold L. ;
Bowman, Marjorie ;
Allan, David ;
Anstee, Grizel ;
Arnold, Douglas L. ;
Bar-Or, Amit ;
Bence-Bruckler, Isabelle ;
Birch, Paul ;
Bredeson, Christopher ;
Chen, Jacqueline ;
Fergusson, Dean ;
Halpenny, Mike ;
Hamelin, Linda ;
Huebsch, Lothar ;
Hutton, Brian ;
Laneuville, Pierre ;
Lapierre, Yves ;
Lee, Hyunwoo ;
Martin, Lisa ;
McDiarmid, Sheryl ;
O'Connor, Paul ;
Ramsay, Timothy ;
Sabloff, Mitchell ;
Walker, Lisa ;
Freedman, Mark S. .
LANCET, 2016, 388 (10044) :576-585
[2]   Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the DEFINE study [J].
Bar-Or, Amit ;
Gold, Ralf ;
Kappos, Ludwig ;
Arnold, Douglas L. ;
Giovannoni, Gavin ;
Selmaj, Krzysztof ;
O'Gorman, John ;
Stephan, Monica ;
Dawson, Katherine T. .
JOURNAL OF NEUROLOGY, 2013, 260 (09) :2297-2305
[3]   Rituximab Use in Pediatric Central Demyelinating Disease [J].
Beres, Shannon J. ;
Graves, Jennifer ;
Waubant, Emmanuelle .
PEDIATRIC NEUROLOGY, 2014, 51 (01) :114-118
[4]   Therapeutic Management of Severe Relapses in Multiple Sclerosis [J].
Bevan, Carolyn ;
Gelfand, Jeffrey M. .
CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2015, 17 (04) :1-14
[5]   Longer term effectiveness of inpatient multidisciplinary rehabilitation on health-related quality of life in MS patients: a pragmatic randomized controlled trial - The Danish MS Hospitals Rehabilitation Study [J].
Boesen, Finn ;
Norgaard, Michael ;
Trenel, Philipp ;
Rasmussen, Peter Vestergaard ;
Petersen, Thor ;
Lovendahl, Brita ;
Sorensen, Jan .
MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (03) :340-349
[6]   Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis [J].
Chitnis, Tanuja ;
Arnold, Douglas L. ;
Banwell, Brenda ;
Brueck, Wolfgang ;
Ghezzi, Angelo ;
Giovannoni, Gavin ;
Greenberg, Benjamin ;
Krupp, Lauren ;
Rostasy, Kevin ;
Tardieu, Marc ;
Waubant, Emmanuelle ;
Wolinsky, Jerry S. ;
Bar-Or, Amit ;
Stites, Tracy ;
Chen, Yu ;
Putzki, Norman ;
Merschhemke, Martin ;
Gaertner, Jutta .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (11) :1017-1027
[7]   Pediatric multiple sclerosis Escalation and emerging treatments [J].
Chitnis, Tanuja ;
Ghezzi, Angelo ;
Bajer-Kornek, Barbara ;
Boyko, Alexey ;
Giovannoni, Gavin ;
Pohl, Daniela .
NEUROLOGY, 2016, 87 (09) :S103-S109
[8]  
Citterio La Mantia., 2013, Cochrane Libr, DOI [DOI 10.1002/14651858.CD001331, 10.1002/14651858.CD001331]
[9]   Effectiveness of Natalizumab in Patients with Highly Active Relapsing Remitting Multiple Sclerosis [J].
Cobo-Calvo, Alvaro ;
Bau, Laura ;
Matas, Elisabet ;
Romero-Pinel, Lucia ;
Mane Martinez, M. Alba ;
Majos, Carles ;
Martinez Yelamos, Sergio .
EUROPEAN NEUROLOGY, 2015, 73 (3-4) :220-229
[10]   Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes [J].
Coles, Alasdair J. ;
Fox, Edward ;
Vladic, Anton ;
Gazda, Suzanne K. ;
Brinar, Vesna ;
Selmaj, Krzysztof W. ;
Doan-Do Bass, Ann ;
Wynn, Daniel R. ;
Margolin, David H. ;
Lake, Stephen L. ;
Moran, Susan ;
Palmer, Jeffrey ;
Smith, M. Shelton ;
Compston, D. Alastair S. .
LANCET NEUROLOGY, 2011, 10 (04) :338-348